Boosted protease inhibitor (PI/r) monotherapy is effective in clinical practice

被引：0
|
作者：
Simpkin, E. [1 ]
Richardson, C. [1 ]
Fisher, M. [1 ]
机构：
[1] BSUH NHS Trust, Brighton, E Sussex, England
来源：
HIV MEDICINE | 2010年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [41] Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
    Arribas, Jose R.
    Doroana, Manuela
    Turner, Dan
    Vandekerckhove, Linos
    Streinu-Cercel, Adrian
    AIDS RESEARCH AND THERAPY, 2013, 10
  • [42] Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy
    Kahlert, C.
    Bregenzer, A.
    Gutmann, C.
    Otterbech, S.
    Hoffmann, M.
    Schmid, P.
    Vernazza, P.
    INFECTION, 2016, 44 (03) : 329 - 335
  • [43] Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI
    Barber, T.
    Harrison, L.
    Asboe, D.
    Williams, I.
    Bansi, L.
    Pillay, D.
    Dunn, D.
    HIV MEDICINE, 2011, 12 : 73 - 74
  • [44] Cost-efficacy analysis of darunavir/r monotherapy in clinical practice
    Perez Elias, M.
    Martinez-Colubi, M.
    Sanz, J.
    Gomez, C.
    Sepulveda, M.
    Estrada, V
    Moreno, A.
    Muriel, A.
    Dronda, F.
    Del Palacio, M.
    Casado, J.
    Gomez-Ayerbe, C.
    Rodriguez Sagrado, M.
    Moreno, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 67 - 68
  • [45] Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy
    C. Kahlert
    A. Bregenzer
    C. Gutmann
    S. Otterbech
    M. Hoffmann
    P. Schmid
    P. Vernazza
    Infection, 2016, 44 : 329 - 335
  • [46] Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract
    Torres-Cornejo, A.
    BenMarzouk-Hidalgo, O. J.
    Viciana, P.
    Sanchez, B.
    Lopez-Ruz, M. A.
    Lopez-Cortes, L. F.
    Gutierrez-Valencia, A.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (01) : 98.e7 - 98.e10
  • [47] Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc
    Katiyar, A.
    Burns, F.
    Swaden, L.
    Youle, M.
    Barber, T.
    HIV MEDICINE, 2020, 21 : 16 - 16
  • [48] Patient compliance and drug failure in protease inhibitor monotherapy
    Vanhove, GF
    Schapiro, JM
    Winters, MA
    Merigan, TC
    Blaschke, TF
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (24): : 1955 - 1956
  • [49] Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc
    Katiyar, A.
    Burns, F.
    Swaden, L.
    Youle, M.
    Barber, T. J.
    HIV MEDICINE, 2019, 20 : 63 - 63
  • [50] Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice
    Cleijsen, R. M. M.
    De Ende, M. E. Van
    Kroon, F. P.
    Lunel, F. Verduyn
    Koopmans, P. P.
    Gras, L.
    De Wolf, F.
    Burger, D. M.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (04) : 897 - 900
12345